Please use this identifier to cite or link to this item:
|Title:||Intraocular pressure-reducing effects and safety of latanoprost versus timolol in patients with chronic angle-closure glaucoma||Authors:||Chew, P.T.K.
|Issue Date:||Mar-2004||Citation:||Chew, P.T.K., Aung, T., Aquino, M.V., Rojanapongpun, P. (2004-03). Intraocular pressure-reducing effects and safety of latanoprost versus timolol in patients with chronic angle-closure glaucoma. Ophthalmology 111 (3) : 427-434. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ophtha.2003.06.007||Abstract:||Objective: To demonstrate that the intraocular pressure (IOP)-reducing effect of latanoprost once daily is at least as good as that of timolol twice daily in patients with chronic angle-closure glaucoma (CACG). Design: Randomized, double-masked, multicenter 12-week study. Participants: In all, 137 patients with unilateral or bilateral CACG were treated with latanoprost, and 138 were treated with timolol. Methods: Patients received either latanoprost (9 PM) and a placebo (9 AM) or timolol (both 9 AM and 9 PM). Intraocular pressure was measured at 9 AM and 5 PM at baseline and weeks 2, 6, and 12. Main Outcome Measures: The difference between groups in daily IOP (average of 9 AM and 5 PM measures) reduction was the primary outcome. Secondary outcomes included differences between groups in IOP reductions at 9 AM and 5 PM, and in proportions of patients reaching specified daily IOP levels. Results: Using repeated measures (analysis of covariance: intent to treat), mean changes from baseline in daily IOP levels during 12 weeks were -8.2 mmHg and -5.2 mmHg for latanoprost- and timolol-treated patients, respectively (difference: -3.0 mmHg [95% confidence interval: -4.0, -2.1], P||Source Title:||Ophthalmology||URI:||http://scholarbank.nus.edu.sg/handle/10635/132602||ISSN:||01616420||DOI:||10.1016/j.ophtha.2003.06.007|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.